Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells
Synonyms
Therapy Description

Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells comprise CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domains and a truncated human epidermal growth factor receptor (EGFRt), which potentially induce cytotoxicity against CD19-expressing tumor cells and antitumor activity (PMID: 28408462, NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T cells CD19 Immune Cell Therapy 62 Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells comprise CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domains and a truncated human epidermal growth factor receptor (EGFRt), which potentially induce cytotoxicity against CD19-expressing tumor cells and antitumor activity (PMID: 28408462, NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06447987 Phase I Cetuximab Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT05625594 Phase I Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Cyclophosphamide + Fludarabine Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma Recruiting USA 0
NCT02028455 Phase Ib/II Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Active, not recruiting USA 0


Additional content available in CKB BOOST